The impact of CYP2C19 genotype on phenoconversion by concomitant medication
Conclusion: This study suggests that the differential outcome of CYP2C19-mediated DDIs between genotypes are primarily dictated by basal CYP2C19 activity, that may in part be predicted by CYP2C19 genotype but likely also depends on disease-related factors.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Diabetes | Drugs & Pharmacology | Endocrinology | Genetics | Liver | Liver Disease | Omeprazole | Pantoprazole | Prilosec | Protonix | Study | Urology & Nephrology